HSAQ vs. PDEX, SRTS, MGRM, ICCM, AMIX, SEPA, LUCD, CTSO, NVNO, and NSPR
Should you be buying Health Sciences Acquisitions Co. 2 stock or one of its competitors? The main competitors of Health Sciences Acquisitions Co. 2 include Pro-Dex (PDEX), Sensus Healthcare (SRTS), Monogram Orthopaedics (MGRM), IceCure Medical (ICCM), Autonomix Medical (AMIX), SEP Acquisition (SEPA), Lucid Diagnostics (LUCD), Cytosorbents (CTSO), enVVeno Medical (NVNO), and InspireMD (NSPR). These companies are all part of the "surgical & medical instruments" industry.
Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, community ranking, risk and valuation.
In the previous week, Pro-Dex had 3 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 4 mentions for Pro-Dex and 1 mentions for Health Sciences Acquisitions Co. 2. Pro-Dex's average media sentiment score of 0.41 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that Pro-Dex is being referred to more favorably in the news media.
89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by company insiders. Comparatively, 42.6% of Pro-Dex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500. Comparatively, Pro-Dex has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.
Pro-Dex has a net margin of 4.13% compared to Health Sciences Acquisitions Co. 2's net margin of 0.00%. Pro-Dex's return on equity of 6.50% beat Health Sciences Acquisitions Co. 2's return on equity.
Pro-Dex has higher revenue and earnings than Health Sciences Acquisitions Co. 2.
Pro-Dex received 146 more outperform votes than Health Sciences Acquisitions Co. 2 when rated by MarketBeat users.
Summary
Pro-Dex beats Health Sciences Acquisitions Co. 2 on 10 of the 11 factors compared between the two stocks.
Get Health Sciences Acquisitions Co. 2 News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSAQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HSAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Health Sciences Acquisitions Co. 2 Competitors List
Related Companies and Tools
